16 December 2015
The Russian pharmaceutical company NovaMedica that is a Rusnano portfolio company will start technological centre construction in Technopolis Moscow to develop and produce on a pilot basis innovative medical products.
The project investment volume amounts to $15 mln. The centre will have laboratories and production areas with technological capabilities. The laboratory capacity is designed for 15 research projects per year. The pilot production capacity is up to 80 mln doses per year. The development plan of NovaMedica technological centre allows to create research workplaces.
According to the CEO of Technopolis Moscow Igor Ishchenko, to date nine companies operating in the area of medicine have come to Technopolis. “We associate this activity on the part of pharmaceutical producers with both the fulfillment of Pharma-2020 Government Program and measures to support the domestic producers as a part of import phase-out program. We have also been working closely with Rusnano and NovaMedica that is the ninth company in our platform for more than three years. At the moment we are negotiating with six more companies which want to open their production in Technopolis Moscow,” Igor Ishchenko stated.
The major task of NovaMedica technological subdivision will be drug development using new technology platforms based on (including, but not limited to) nanotechnologies. The company is focused on development of innovative dosage forms that will allow changing bioavailability of active agents and combining the substances, which have been incompatible earlier. It is suggested to promote company inventions not only in Russia but also in international markets.
16 October 2018
15 October 2018
15 October 2018
12 October 2018